Safety and immunogenicity of the live-attenuated hRVFV-4s vaccine against Rift Valley fever in healthy adults: a dose-escalation, placebo-controlled, first-in-human, phase 1 randomised clinical trial.

Leroux-Roels I, Prajeeth CK, Aregay A, Nair N, Rimmelzwaan GF, Osterhaus ADME, Kardinahl S, Pelz S, Bauer S, D'Onofrio V, Alhatemi A, Jacobs B, De Boever F, Porrez S, Waerlop G, Punt C, Hendriks B, von Mauw E, van de Water S, Harders-Westerveen J, Rockx B, van Keulen L, Kortekaas J, Leroux-Roels G, Wichgers Schreur PJ.

Open source

DOI: 10.1016/s1473-3099(24)00375-x
Published: 2024-07-25
Container: Lancet Infect Dis
Publisher: Not recorded
Open access: no

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/s1473-3099-24-00375-x,
  title = {Safety and immunogenicity of the live-attenuated hRVFV-4s vaccine against Rift Valley fever in healthy adults: a dose-escalation, placebo-controlled, first-in-human, phase 1 randomised clinical trial.},
  author = {Leroux-Roels I and  Prajeeth CK and  Aregay A and  Nair N and  Rimmelzwaan GF and  Osterhaus ADME and  Kardinahl S and  Pelz S and  Bauer S and  D'Onofrio V and  Alhatemi A and  Jacobs B and  De Boever F and  Porrez S and  Waerlop G and  Punt C and  Hendriks B and  von Mauw E and  van de Water S and  Harders-Westerveen J and  Rockx B and  van Keulen L and  Kortekaas J and  Leroux-Roels G and  Wichgers Schreur PJ.},
  year = {2024},
  journal = {Lancet Infect Dis},
  doi = {10.1016/s1473-3099(24)00375-x},
  url = {https://doi.org/10.1016/s1473-3099(24)00375-x}
}

RIS

TY  - JOUR
TI  - Safety and immunogenicity of the live-attenuated hRVFV-4s vaccine against Rift Valley fever in healthy adults: a dose-escalation, placebo-controlled, first-in-human, phase 1 randomised clinical trial.
AU  - Leroux-Roels I
AU  -  Prajeeth CK
AU  -  Aregay A
AU  -  Nair N
AU  -  Rimmelzwaan GF
AU  -  Osterhaus ADME
AU  -  Kardinahl S
AU  -  Pelz S
AU  -  Bauer S
AU  -  D'Onofrio V
AU  -  Alhatemi A
AU  -  Jacobs B
AU  -  De Boever F
AU  -  Porrez S
AU  -  Waerlop G
AU  -  Punt C
AU  -  Hendriks B
AU  -  von Mauw E
AU  -  van de Water S
AU  -  Harders-Westerveen J
AU  -  Rockx B
AU  -  van Keulen L
AU  -  Kortekaas J
AU  -  Leroux-Roels G
AU  -  Wichgers Schreur PJ.
PY  - 2024
JO  - Lancet Infect Dis
DO  - 10.1016/s1473-3099(24)00375-x
UR  - https://doi.org/10.1016/s1473-3099(24)00375-x
ER  -

APA

I, L., CK, P., A, A., N, N., GF, R., ADME, O., S, K., S, P., S, B., V, D., A, A., B, J., F, D. B., S, P., G, W., C, P., B, H., E, V. M., S, V. D. W., J, H., B, R., L, V. K., J, K., G, L., & PJ., W. S. (2024). Safety and immunogenicity of the live-attenuated hRVFV-4s vaccine against Rift Valley fever in healthy adults: a dose-escalation, placebo-controlled, first-in-human, phase 1 randomised clinical trial.. Lancet Infect Dis. https://doi.org/10.1016/s1473-3099(24)00375-x

Source records

europe-pmc · retrieved 2026-09-26T08:16:36.808Z